Compare PFAI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFAI | ATNM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 31.7M |
| IPO Year | 2024 | 2013 |
| Metric | PFAI | ATNM |
|---|---|---|
| Price | $2.56 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 5.1K | ★ 151.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.46 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.78 | $0.74 |
| 52 Week High | $4.93 | $1.74 |
| Indicator | PFAI | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 57.45 |
| Support Level | $2.16 | $0.98 |
| Resistance Level | $3.10 | $1.13 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 87.14 | 38.89 |
Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.